Abstract 10467: Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease despite advances in targeted therapies. Sotatercept, a first-in-class activin receptor type IIA ligand trap, targets pulmonary vascular remodeling and may provide a disease-modifying treatment approach. Research question: We aimed to evaluate the efficacy and safety of sotatercept in patients with PAH. Methods: A systematic review and meta-analysis of randomized controlled trials evaluating sotatercept in patients with PAH was conducted according to PRISMA guidelines. PubMed/MEDLINE, Cochrane Library, and Google Scholar were searched from inception through April 2026. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool. Results: Five randomized controlled trials comprising 1,031 patients were included. Compared with placebo, sotatercept significantly improved 6-minute walk distance (MD 30.77, 95% CI 15.19-46.36), WHO functional class improvement (RR 1.70, 95% CI 1.37-2.11), pulmonary vascular resistance (MD -237.46, 95% CI -292.55 to -182.38), mean pulmonary artery pressure (MD -14.85, 95% CI -19.57 to -10.14), NT-proBNP (MD -1134.11, 95% CI -2025.21 to -243.01), right atrial pressure (MD -2.58, 95% CI -3.30 to -1.86), and cardiac output (MD 0.24, 95% CI 0.06-0.42). No significant differences were observed in all-cause mortality, overall adverse events, or treatment discontinuation. However, sotatercept was associated with higher risks of bleeding events (RR 1.84, 95% CI 1.40-2.43) and hypertension (RR 3.34, 95% CI 1.35-8.25). Conclusion: Sotatercept significantly improves functional capacity, hemodynamic parameters, and biomarkers in patients with pulmonary hypertension while demonstrating an acceptable overall safety profile. Although bleeding events and hypertension were more frequent, sotatercept represents a promising adjunctive therapy for pulmonary arterial hypertension.